

Amendments to the Specification

Please replace the paragraph starting on page 36, line 28 to page 37, line 9 with the following amended paragraph:

The invention also features a method of treating cancer, including prostate cancer and acute myelogenous leukemia, in a mammal, e.g., a human. The method of treating acute myelogenous leukemia includes formulating a fused pyrrolocarbazole in a non-aqueous, fused pyrrolocarbazole-containing, particle-forming composition containing a surfactant in an amount of at least 20% (w/w), and administering a therapeutically effective amount of the particle-forming composition to the mammal. In one embodiment of the method, the particle-forming composition is contacted with an aqueous medium *in vitro*, to form a stable suspension. A therapeutically effective amount of the stable suspension is then administered to the mammal. In an alternative embodiment, a therapeutically effective amount of the particle-forming composition is administered directly to the mammal, where it contacts an aqueous medium *in vivo*.